Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models

Virology

Volumn 375, Issue 2, 2008, Pages 529-538

  Brown, Bruce K ^a   Wieczorek, Lindsay ^a   Sanders Buell, Eric ^a   Borges, Andrew Rosa ^a   Robb, Merlin L ^a   Birx, Deborah L ^b,c   Michael, Nelson L ^b   McCutchan, Francine E ^a   Polonis, Victoria R ^b  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Cross clade; HIV 1 neutralization; Primary isolate; Pseudovirus; TZM bl reporter cells

Indexed keywords

NEUTRALIZING ANTIBODY;

ARTICLE; CLADISTICS; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PANDEMIC; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SERODIAGNOSIS; VIRUS STRAIN;

AIDS VACCINES; ANTIBODY SPECIFICITY; CELLS, CULTURED; CROSS REACTIONS; DISEASE OUTBREAKS; HELA CELLS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; NEUTRALIZATION TESTS; SENSITIVITY AND SPECIFICITY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 43249120051     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.02.022     Document Type: Article

References (58)

1. Albert J., Abrahamsson B., Nagy K., Aurelius E., Gaines H., Nystrom G., and Fenyo E.M. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. Aids 4 2 (1990) 107-112
2. Baba T.W., Liska V., Hofmann-Lehmann R., Vlasak J., Xu W., Ayehunie S., Cavacini L.A., Posner M.R., Katinger H., Stiegler G., Bernacky B.J., Rizvi T.A., Schmidt R., Hill L.R., Keeling M.E., Lu Y., Wright J.E., Chou T.C., and Ruprecht R.M. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat. Med. 6 2 (2000) 200-206
3. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 23 (2004) 13232-13252
4. Brown A.E., and McNeil J.G. HIV vaccine development: a subtype E-specific strategy. Southeast Asian J. Trop. Med. Public Health 29 2 (1998) 377-382
5. Brown B.K., Darden J.M., Tovanabutra S., Oblander T., Frost J., Sanders-Buell E., de Souza M.S., Birx D.L., McCutchan F.E., and Polonis V.R. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J. Virol. 79 10 (2005) 6089-6101
6. Brown B.K., Karasavvas N., Beck Z., Matyas G.R., Birx D.L., Polonis V.R., and Alving C.R. Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites. J. Virol. 81 4 (2007) 2087-2091
7. Bures R., Morris L., Williamson C., Ramjee G., Deers M., Fiscus S.A., Abdool-Karim S., and Montefiori D.C. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J. Virol. 76 5 (2002) 2233-2244
8. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., and Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 3 (2004) 233-236
9. Choudhry V., Zhang M.Y., Harris I., Sidorov I.A., Vu B., Dimitrov A.S., Fouts T., and Dimitrov D.S. Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. Biochem. Biophys. Res. Commun. 348 3 (2006) 1107-1115
10. Darden J.M., Polonis V.R., deSouza M.S., Chantakulkij S., Brown A.E., Birx D.L., and Pattanapanyasat K. A flow cytometric method for measuring neutralization of HIV-1 subtype B and E primary isolates. Cytometry 40 2 (2000) 141-150
11. Derdeyn C.A., Decker J.M., Bibollet-Ruche F., Mokili J.L., Muldoon M., Denham S.A., Heil M.L., Kasolo F., Musonda R., Hahn B.H., Shaw G.M., Korber B.T., Allen S., and Hunter E. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303 5666 (2004) 2019-2022
12. Frost S.D., Liu Y., Pond S.L., Chappey C., Wrin T., Petropoulos C.J., Little S.J., and Richman D.D. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J. Virol. 79 10 (2005) 6523-6527
13. Hanson C.V., Crawford-Miksza L., and Sheppard H.W. Application of a rapid microplaque assay for determination of human immunodeficiency virus neutralizing antibody titers. J. Clin. Microbiol. 28 9 (1990) 2030-2034
14. Hioe C.E., Bastiani L., Hildreth J.E., and Zolla-Pazner S. Role of cellular adhesion molecules in HIV type 1 infection and their impact on virus neutralization. AIDS Res. Hum. Retrovir. 14 Suppl 3 (1998) S247-S254
15. Holl V., Peressin M., Decoville T., Schmidt S., Zolla-Pazner S., Aubertin A.M., and Moog C. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. J. Virol. 80 12 (2006) 6177-6181
16. Ketas T.J., Kuhmann S.E., Palmer A., Zurita J., He W., Ahuja S.K., Klasse P.J., and Moore J.P. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology 364 2 (2007) 281-290
17. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 16 2 (1980) 111-120
18. Kong W.P., Huang Y., Yang Z.Y., Chakrabarti B.K., Moodie Z., and Nabel G.J. Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines. J. Virol. 77 23 (2003) 12764-12772
19. Kostrikis L.G., Cao Y., Ngai H., Moore J.P., and Ho D.D. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J. Virol. 70 1 (1996) 445-458
20. Kostrikis L.G., Michalopoulou Z.H., Cao Y., Moore J.P., and Ho D.D. Determining neutralization serotypes of HIV type 1 by neural networks. AIDS Res. Hum. Retrovir. 12 18 (1996) 1667-1669
21. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 16 (2005) 10108-10125
22. Li B., Decker J.M., Johnson R.W., Bibollet-Ruche F., Wei X., Mulenga J., Allen S., Hunter E., Hahn B.H., Shaw G.M., Blackwell J.L., and Derdeyn C.A. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J. Virol. 80 11 (2006) 5211-5218
23. Mascola J.R. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 20 15 (2002) 1922-1925
24. Mascola J.R., Louwagie J., McCutchan F.E., Fischer C.L., Hegerich P.A., Wagner K.F., Fowler A.K., McNeil J.G., and Burke D.S. Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J. Infect. Dis. 169 1 (1994) 48-54
25. Mascola J.R., Louder M.K., Surman S.R., Vancott T.C., Yu X.F., Bradac J., Porter K.R., Nelson K.E., Girard M., McNeil J.G., McCutchan F.E., Birx D.L., and Burke D.S. Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res. Hum. Retrovir. 12 14 (1996) 1319-1328
26. Mascola J.R., Snyder S.W., Weislow O.S., Belay S.M., Belshe R.B., Schwartz D.H., Clements M.L., Dolin R., Graham B.S., Gorse G.J., Keefer M.C., McElrath M.J., Walker M.C., Wagner K.F., McNeil J.G., McCutchan F.E., and Burke D.S. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 173 2 (1996) 340-348
27. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., Beary H., Hayes D., Frankel S.S., Birx D.L., and Lewis M.G. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6 2 (2000) 207-210
28. Mascola J.R., Louder M.K., Winter C., Prabhakara R., De Rosa S.C., Douek D.C., Hill B.J., Gabuzda D., and Roederer M. Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells. J. Virol. 76 10 (2002) 4810-4821
29. Mascola J.R., D'Souza P., Gilbert P., Hahn B.H., Haigwood N.L., Morris L., Petropoulos C.J., Polonis V.R., Sarzotti M., and Montefiori D.C. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 79 16 (2005) 10103-10107
30. Matthews T.J. Dilemma of neutralization resistance of HIV-1 field isolates and vaccine development. AIDS Res. Hum. Retrovir. 10 6 (1994) 631-632
31. McCutchan F.E. Understanding the genetic diversity of HIV-1. Aids 14 Suppl 3 (2000) S31-S44
32. McCutchan F.E., Sanders-Buell E., Salminen M.O., Carr J.K., and Sheppard W.H. Diversity of the human immunodeficiency virus type 1 envelope glycoprotein in San Francisco Men's Health Study participants. AIDS Res. Hum. Retrovir. 14 4 (1998) 329-337
33. McMichael A.J. HIV vaccines. Annu. Rev. Immunol. 24 (2006) 227-255
34. Montefiori D. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. In: Coicko R. (Ed). Current Protocols in Immunology (2004), John Wiley & Sons, New York, New York 12.11.1-12.11.15
35. Moore J.P., Cao Y., Leu J., Qin L., Korber B., and Ho D.D. Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. J. Virol. 70 1 (1996) 427-444
36. Nabel G.J. HIV vaccine strategies. Vaccine 20 15 (2002) 1945-1947
37. Nara P.L., and Fischinger P.J. Quantitative infectivity assay for HIV-1 and -2. Nature 332 6163 (1988) 469-470
38. Nishimura Y., Igarashi T., Haigwood N.L., Sadjadpour R., Donau O.K., Buckler C., Plishka R.J., Buckler-White A., and Martin M.A. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl. Acad. Sci. U. S. A. 100 25 (2003) 15131-15136
39. Nitayaphan S., and Brown A.E. Preventive HIV vaccine development in Thailand. Aids 12 (1998) S155-S161 Suppl B
40. Nyambi P.N., Nkengasong J., Lewi P., Andries K., Janssens W., Fransen K., Heyndrickx L., Piot P., and van der Groen G. Multivariate analysis of human immunodeficiency virus type 1 neutralization data. J. Virol. 70 9 (1996) 6235-6243
41. Nyambi P.N., Nadas A., Mbah H.A., Burda S., Williams C., Gorny M.K., and Zolla-Pazner S. Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J. Virol. 74 22 (2000) 10670-10680
42. Parren P.W., Marx P.A., Hessell A.J., Luckay A., Harouse J., Cheng-Mayer C., Moore J.P., and Burton D.R. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75 17 (2001) 8340-8347
43. Petropoulos C.J., Parkin N.T., Limoli K.L., Lie Y.S., Wrin T., Huang W., Tian H., Smith D., Winslow G.A., Capon D.J., and Whitcomb J.M. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44 4 (2000) 920-928
44. Polonis V.R., et al. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 375 (2008) 315-320
45. Rademeyer C., Moore P.L., Taylor N., Martin D.P., Choge I.A., Gray E.S., Sheppard H.W., Gray C., Morris L., and Williamson C. Genetic characteristics of HIV-1 subtype C envelopes inducing cross-neutralizing antibodies. Virology 368 1 (2007) 172-181
46. Richman D.D., Wrin T., Little S.J., and Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100 7 (2003) 4144-4149
47. Robert-Guroff M., Reitz Jr. M.S., Robey W.G., and Gallo R.C. In vitro generation of an HTLV-III variant by neutralizing antibody. J Immunol 137 10 (1986) 3306-3309
48. Salminen M.O., Carr J.K., Robertson D.L., Hegerich P., Gotte D., Koch C., Sanders-Buell E., Gao F., Sharp P.M., Hahn B.H., Burke D.S., and McCutchan F.E. Evolution and probable transmission of intersubtype recombinant human immunodeficiency virus type 1 in a Zambian couple. J. Virol. 71 4 (1997) 2647-2655
49. Salminen M.O., Koch C., Sanders-Buell E., Ehrenberg P.K., Michael N.L., Carr J.K., Burke D.S., and McCutchan F.E. Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. Virology 213 1 (1995) 80-86
50. Shibata R., Igarashi T., Haigwood N., Buckler-White A., Ogert R., Ross W., Willey R., Cho M.W., and Martin M.A. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 5 2 (1999) 204-210
51. Srivastava I.K., Ulmer J.B., and Barnett S.W. Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design. Expert Rev. Vaccines 3 4 Suppl (2004) S33-S52
52. Verrier F., Burda S., Belshe R., Duliege A.M., Excler J.L., Klein M., and Zolla-Pazner S. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates. J. Virol. 74 21 (2000) 10025-10033
53. Wainberg M.A. HIV-1 subtype distribution and the problem of drug resistance. Aids 18 Suppl 3 (2004) S63-S68
54. Wang L.X. Bioorganic approaches towards HIV vaccine design. Curr. Pharm. Des. 9 22 (2003) 1771-1787
55. Weber J., Fenyo E.M., Beddows S., Kaleebu P., and Bjorndal A. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. J. Virol. 70 11 (1996) 7827-7832
56. Wrin T., Loh T.P., Vennari J.C., Schuitemaker H., and Nunberg J.H. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J. Virol. 69 1 (1995) 39-48
57. Zolla-Pazner S. Mechanisms contributing to the neutralization of HIV-1. Immunol. Lett. 51 1-2 (1996) 89-93
58. Zolla-Pazner S., and Sharpe S. A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates. AIDS Res. Hum. Retrovir. 11 12 (1995) 1449-1458